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Introduction
Diabetes mellitus (DM) is a risk factor for cardiovascular
disease (CVD) [1]. Both traditional and nontraditional
molecules have been explored to explain the development
of DM-related CVD. Molecules associated with the circu-
latory system, such as the natriuretic peptides, which are
counterregulatory hormones involved in the regulation of
volume homeostasis and cardiovascular remodeling, are an
important clue for understanding the underlying mecha-
nisms of DM-related CVD [2]. The plasma brain natriuretic
peptide (BNP) level is thus a predictor of CVD events and
death [3]. Additionally, the oxidative stress burden may in
part explain the link between DM and CVD [4]. Although
several markers are applicable, the diacron reactive oxygen
metabolites (d-ROMs) test and malondialdehyde (MDA)
are indicators of the global oxidative stress burden in a
clinical setting [5], especially in patients with type 2 DM
(T2DM) [6, 7].
Liraglutide, a long-acting glucagon-like receptor peptide
(GLP)-1 analogue, is a recent treatment modality that may
tolerably improve glycemic control [8–10] and provide
beneficial cardiovascular effects via extrapancreatic mech-
anisms [11, 12]. Clinical studies of the association between
liraglutide and cardiovascular risk markers, especially non-
traditional markers, have been limited. The aim of the
present study was to investigate the effects of 24 weeks of
treatment with liraglutide on cardiovascular risk markers
such as BNP, d-ROMs, and MDA in patients with T2DM.
Subjects and methods
Sixty-five adult outpatients with T2DM (37 men and 28
women) were treated with liraglutide for 24 weeks. Eligi-
bility criteria included the absence of pregnancy, an esti-
mated duration of DM of no more than 15 years, no history
of treatment with insulin, and a target hemoglobin A1c
(HbA1c) [7.0 % even with diet and exercise therapy. We
excluded patients with a recent acute illness, inflammatory
bowel disease, a history of ileus, severe nephropathy (i.e.,
stage 3–5), liver dysfunction, and type 1 DM. The study
protocol was approved by the Jichi Medical University
Ethical Committee, and written informed consent was
obtained from all participants. If patients were being trea-
ted with antiglycemic agents, we discontinued use of
a-glucosidase inhibitors, pioglitazone, metformin, and
dipeptidyl peptidase 4 inhibitors when treatment with
liraglutide was initiated because the health insurance sys-
tem in Japan indicates that these medications should not be
administered with liraglutide. Therefore, no hypoglycemic
agents except sulfonylureas were used in this study.
Treatment with liraglutide was initiated at a dosage of
0.3 mg/day and titrated up to 0.6–0.9 mg/day when
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necessary. The dosage of liraglutide or a sulfonylurea was
decreased if the glycemic target of fasting glucose was less
than 95 mg/dL or causing hypoglycemic symptoms. When
treatment with liraglutide was initiated, the dosage of the
sulfonylurea was decreased by half.
At baseline and after 24 weeks of treatment, weight,
systolic/diastolic blood pressure, and heart rate were mea-
sured and blood/urine samples were collected for measure-
ment of the following parameters: HbA1c, glucose, total
cholesterol, triglyceride, high-density lipoprotein choles-
terol, aspartate aminotransferase, alanine aminotransferase,
c-glutamyl transpeptidase, urine albumin, BNP, d-ROMs,
and MDA. Plasma BNP levels were measured using an im-
munoenzymometric assay kit (E-Test TOSOH II [BNP];
Tosoh Corp., Tokyo, Japan) [13]. The d-ROMs values were
obtained using a kinetic spectrophotometric assay (F.R.E.E.
System; Diacron, Grosseto, Italy) [5]. The MDA values were
measured using a commercially available kit (Cell Biolabs
Inc., San Diego, CA, USA).
The data are presented as mean ± standard deviation for
parametric variables, medians and interquartile ranges for
nonparametric variables, or numbers for categorical vari-
ables. In all analyses, the variables with nonparametric
distributions were treated after a log transformation. Paired
t tests were used to examine the changes in respective
parameters. Correlations between changes in variables
were examined using Pearson correlation tests. Statistical
significance was set at a P value of \0.05.
Results
No patients dropped out of this study. The patients were
58.7 ± 10.2 years of age, body mass index was
27.9 ± 5.9 kg/m2, and duration of DM was 7.0 years.
Before this study, 24 patients (36.9 %) had not been treated
with an antidiabetic agent and 41 patients (63.1 %) had
been treated with a sulfonylurea (n = 32), dipeptidyl
peptidase 4 inhibitor (n = 18), or metformin (n = 15).
After 24 weeks of treatment with liraglutide (mean dose,
0.74 mg), both HbA1c and blood glucose levels were sig-
nificantly reduced (Table 1), as well as systolic and diastolic
blood pressure. A significant decrease in urine albumin
(mean 23.5–12.7 mg/g Cr), BNP (mean 9.2–6.3 pg/mL),
and d-ROMs (mean 416.2–384.8 U. CARR) levels was also
observed after treatment. There were no significant differ-
ences in body weight, body mass index, heart rate, lipid
levels, liver function markers, and MDA levels.
A correlation analysis revealed that the change in BNP
levels was significantly and negatively correlated to that of
HbA1c (r = - 0.30, P = 0.02) or positively to that of
systolic blood pressure (r = 0.26, P = 0.046). The change
in d-ROMs levels was significantly and positively corre-
lated to that of MDA (r = 0.38, P \ 0.01) or that of HbA1c
(r = 0.25, P = 0.049). The change in MDA levels was not
correlated to that of HbA1c. The change in urine albumin
levels was significantly and positively correlated to that of
HbA1c (r = 0.45, P \ 0.01) but did not significantly cor-
relate to the changes in blood pressure.
Discussion
The cardioprotective effects of liraglutide, which is now
widely accepted as useful for glycemic control, were
described in a recent review of the literature [10]; however,
these effects were examined in basic studies or short-term
human trials [14], and new nontraditional markers (e.g.,
adipokines) have been reported to be involved in such
cardioprotective mechanisms [9]. In the current study, after
24 weeks of treatment with liraglutide, a significant
Table 1 Clinical data for each variable at baseline and after treat-
ment with liraglutide
Parameters Baseline Week 24 P value
Body weight (kg) 72.6 ± 16.0 72.1 ± 16.4 0.88
Body mass index (kg/m2) 27.9 ± 5.9 27.8 ± 6.0 0.93
Systolic blood pressure
(mmHg)
133 ± 10 126 ± 10 \0.01**
Diastolic blood pressure
(mmHg)
80 ± 10 76 ± 9 \0.02*
Heart rate (beats/min) 82 ± 13 83 ± 11 0.65
HbA1c (%) 9.6 ± 1.7 7.1 ± 0.9 \0.01**
Glucose (mg/dL) 228 ± 99 141 ± 46 \0.01**
Total cholesterol (mg/dL) 199 ± 37 189 ± 30 0.11
Triglyceride (mg/dL) 133 (92–194) 130 (94–163) 0.88
HDL cholesterol (mg/dL) 56 ± 14 56 ± 14 0.52
LDL cholesterol (mg/dL) 109 ± 35 103 ± 30 0.23
AST (IU/L) 23 (21–45) 27 (19–36) 0.71
ALT (IU/L 30 (21–45) 30 (23–42) 0.18
c-GT (IU/L) 37 (23–57) 40 (26–57) 0.99










d-ROMs (U. CARR) 416.2 ± 73.9 384.8 ± 64.9 0.01*
MDA (pmol/mg) 72.4 ± 36.4 69.4 ± 36.7 0.65
HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-
density lipoprotein, AST aspartate aminotransferase, ALT alanine
aminotransferase, GT glutamyl transpeptidase, BNP brain natriuretic
peptide, d-ROMs diacron reactive oxygen metabolites, MDA mal-
ondialdehyde. Data are presented as the mean ± standard deviation
or median (interquartile range). P value comparison of respective data
at baseline and after 24 weeks of treatment. Significance level:
* P \ 0.05; ** P \ 0.01
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reduction was observed not only in levels of glucose,
HbA1c, blood pressure, and urine albumin but also BNP
and d-ROMs, which are nontraditional but potential
markers that may in part explain the link between DM and
CVD in patients with T2DM.
Discrepant findings of increased BNP levels resulting in
weight loss and adipocyte lipolysis been reported in obese
patients with T2DM [15]. The investigators discussed the
effects of weight reduction on the change in BNP levels in
their study [15]; the fact that no weight change was
observed in the current study may partly affect this dis-
crepancy in the direction of the change in BNP levels and
merits further investigation.
The significant correlation between the change in
d-ROMs levels and glycemic control in the current study
might suggest a pleiotropic effect of liraglutide against
CVD by alleviation of the oxidative stress burden in
T2DM. The d-ROMs (reflecting the hydroperoxides of
wide organic compounds of not only lipids but also pro-
teins and nucleic acids [5]) and MDA (reflecting an end
product of lipid peroxidation [7, 16]) can be different
oxidative stress markers. The reduction of d-ROMs but not
MDA levels indicates a possible effect of liraglutide on
oxidative stress through reduced levels of proteins and/or
nucleic acids more than lipid peroxidation. On the other
hand, the reduction of the d-ROMs levels was not very
large, so its relevance in CVD outcomes remains to be
determined. A pleiotropic effect is plausible but should be
further established. Additionally, this study has the limi-
tations of a small sample size, a single-arm design, and a
short-term duration. These limitations must be addressed.
In summary, treatment with liraglutide may exert a
cardioprotective action and partly alleviate the burden of
oxidative stress as a possible pleiotropic action in outpa-
tients with T2DM. These data are preliminary, and future
work is warranted.
Conflict of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. M.H. Davidson, Cardiovascular risk factors in a patient with
diabetes mellitus and coronary artery disease: therapeutic
approaches to improve outcomes: perspectives of a preventive
cardiologist. Am. J. Cardiol. 110(9 Suppl), 43B–49B (2012)
2. E.R. Levin, D.G. Gardner, W.K. Samson, Natriuretic peptides.
N. Engl. J. Med. 339, 321–328 (1998)
3. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, T.
Omland, P.A. Wolf, R.S. Vasan, Plasma natriuretic peptide levels
and the risk of cardiovascular events and death. N. Engl. J. Med.
350, 655–663 (2004)
4. A.C. Maritim, R.A. Sanders, J.B. Watkins 3rd, Diabetes, oxida-
tive stress, and antioxidants: a review. J. Biochem. Mol. Toxicol.
17, 24–38 (2003)
5. C. Vassalle, An easy and reliable automated method to estimate
oxidative stress in the clinical setting. Methods Mol. Biol. 477,
31–39 (2008)
6. I.N. Migdalis, P. Triantafilou, E. Petridou, N. Varvarigos, V.
Totolos, A. Rigopoulos, Lipid peroxides in type 2 diabetic
patients with neuropathy. Res. Commun. Mol. Pathol. Pharmacol.
117–118, 5–12 (2005)
7. R. Sayın, M. Aslan, M.E. Kucukoglu, A. Luleci, M. Atmaca, R.
Esen, H. Demir, Serum prolidase enzyme activity and oxidative
stress levels in patients with diabetic neuropathy. Endocrine
(2013). doi:10.1007/s12020-013-0136-3
8. K.B. Degn, C.B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V.
Chandramouli, J. Rungby, B.R. Landau, O. Schmitz, One week’s
treatment with the long-acting glucagon-like peptide 1 derivative
liraglutide (NN2211) markedly improves 24-h glycemia and
alpha- and beta-cell function and reduces endogenous glucose
release in patients with type 2 diabetes. Diabetes 53, 1187–1194
(2004)
9. G. Dı´az-Soto, D.A. de Luis, R. Conde-Vicente, O. Izaola-Jaure-
gui, C. Ramos, E. Romero, Beneficial effects of liraglutide on
adipocytokines, insulin sensitivity parameters and cardiovascular
risk biomarkers in patients with type 2 diabetes: a prospective
study. Diabetes Res. Clin. Pract. (2014). doi:10.1016/j.diabres.
2014.01.019
10. C.B. Giorda, E. Nada, B. Tartaglino, Pharmacokinetics, safety,
and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in
patients with type 2 diabetes mellitus and renal or hepatic
impairment. A systematic review of the literature. Endocrine
(2014). doi:10.1007/s12020-014-0179-0
11. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q.
Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain,
D.J. Drucker, GLP-1R agonist liraglutide activates cytoprotective
pathways and improves outcomes after experimental myocardial
infarction in mice. Diabetes 58, 975–983 (2009)
12. J.P. Courre`ges, T. Vilsbøll, M. Zdravkovic, T. Le-Thi, T. Krarup,
O. Schmitz, R. Verhoeven, I. Buga´n˜ova´, S. Madsbad, Beneficial
effects of once-daily liraglutide, a human glucagon-like peptide-1
analogue, on cardiovascular risk biomarkers in patients with type
2 diabetes. Diabet. Med. 25, 1129–1131 (2008)
13. Y. Notsu, E. Fukuma, H. Shibata, J. Masuda, Y. Ishibashi,
Evaluation of plasma brain natriuretic peptide concentration used
by AIA-360. Jpn. J. Med. Pharm. Sci. 52, 397–402 (2004)
14. N. Mikhail, Effects of incretin-based therapy in patients with
heart failure and myocardial infarction. Endocrine (2014). doi:10.
1007/s12020-014-0175-4
15. C.J. Li, Q. Yu, P. Yu, T.L. Yu, Q.M. Zhang, S. Lu, D.M. Yu,
Changes in liraglutide-induced body composition are related to
modifications in plasma cardiac natriuretic peptides levels in
obese type 2 diabetic patients. Cardiovasc. Diabetol. (2014).
doi:10.1186/1475-2840-13-36
16. G. Noberaseo, P. Odetti, D. Boeri, M. Maiello, L. Adezati,
Malondialdehyde (MDA) level in diabetic subjects. Relationship
with blood glucose and glycated hemoglobin. Biomed. Phar-
macother. 45, 193–196 (1991)
964 Endocrine (2014) 47:962–964
123
